Product Description
Etidronic Acid is as a member of the family of drugs known as bisphosphonates, etidronate differs from endogenous pyrophosphate in its resistance to enzymatic hydrolysis. This agent adsorbs to hydroxyapatite cells and reduces the number of osteoclasts, thereby inhibiting abnormal bone resorption. Etidronate may also directly stimulate bone formation by osteoblasts. (NCI) (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Etidronic-acid)
Mechanisms of Action: Bone Resorption Inhibitor,Hydroxyapatite Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Canada | Chile | Colombia | Egypt | Germany | Greece | India | Ireland | Italy | Korea | Morocco | New Zealand | Pakistan | Peru | Portugal | Russia | Slovenia | Spain | Sweden | Taiwan | Turkey | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Dainippon Sumitomo Pharma America
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Bone Cancer|Movement Disorders|Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CALCIFADE trial | P2 |
Active, not recruiting |
Movement Disorders |
2027-03-20 |
|
| CTR20181152 | P2 |
Completed |
Prostate Cancer|Bone Cancer |
2022-06-16 |
|
| CTR20200377 | P2 |
Recruiting |
Bone Cancer|Prostate Cancer |
None |